Apollo Hospital Seshadripuram Introduces India’s First MRI Fusion TRUS Guided Trans-Perineal Targeted Biopsy for Prostate Cancer Detection
Apollo Hospital Seshadripuram has pioneered a breakthrough in prostate cancer diagnosis with the introduction of India’s first MRI Fusion TRUS (Transrectal Ultrasound) guided Trans-Perineal Targeted Biopsy. This cutting-edge technology significantly improves cancer detection accuracy to 95–97%, a level previously unattainable with conventional methods.
Dr. Manohar T, Chief of Urology, Uro-Oncology & Kidney Transplantation at Apollo Hospital Seshadripuram and Director of Apollo Institute of Renal Sciences (AIRS), is the first Indian doctor to successfully perform 42 procedures using this advanced biopsy technique.
About the Procedure:
The process begins with a multi-parametric MRI (mpMRI) to identify suspicious lesions on the prostate, which are then mapped using specialized software. The imaging is combined with transrectal ultrasound scans to precisely target the lesions. A fine needle is then inserted through the perineum (area between the scrotum and anus) to collect tissue samples, minimizing the risk of infection associated with the traditional transrectal biopsy. This method allows for targeted and sector biopsies under local, regional, or general anesthesia.
Advantages:
Prostate cancer accounts for 7.1% of male cancers in India, with early diagnosis critical for improving survival.
Traditional biopsy methods miss 25–45% of cancers and carry infection risks.
The new trans-perineal approach improves detection accuracy to 95–97%, with high sensitivity and specificity.
It eliminates the need for bowel preparation or pre-operative antibiotics.
It accesses both upper and lower halves of the prostate, unlike transrectal biopsies limited to the lower half.
Capable of detecting cancers as small as 2mm, facilitating early-stage diagnosis and better treatment outcomes.
Dr. Manohar emphasized the technical expertise required to perform this procedure and its potential to transform prostate cancer care in India.
Leadership Statements:
Dr. Manish Mattoo, CEO of Apollo Hospitals Karnataka Region, stated, “This pioneering technology will play a key role in making prostate cancer curable by enabling early detection and improving patients’ quality of life.”
Mr. Uday Davda, Unit Head at Apollo Hospitals Seshadripuram, added, “We are proud to be part of this revolutionary advancement in cancer diagnosis, reaffirming Apollo’s commitment to healthcare innovation in India.”
.jpg)